Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 12/20 | 1.00 |
| ▸ | ANPEP | P15144 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.99 |
| ▸ | NPC1 | O15118 | 1/20 | 0.99 |
| ▸ | RAB9A | P51151 | 1/20 | 0.99 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.99 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL14583797 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL12799451 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22409382 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL18190282 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21306559 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL24206459 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20815730 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22348910 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21481061 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL3042415 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296223-A1 | METHOD FOR REGULATING SKIN PIGMENTATION | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-02 | — | — | US | claimed |
| CN-103917229-A | Method of regulating skin pigmentation | GEN HOSPITAL CORP | 2014-07-09 | — | — | CN | claimed |
| WO-2013033520-A1 | A METHOD FOR REGULATING SKIN PIGMENTATION | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-07 | — | — | WO | claimed |
| US-20210277044-A1 | NOVEL MOLECULES FOR TARGETING RIBOSOMES AND RIBOSOME-INTERACTING PROTEINS, AND USES THEREOF | IMMAGINA BIOTECHNOLOGY S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-07-06 | — | — | US | disclosed |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-05-18 | — | — | US | disclosed |
| US-10976306-B2 | Protein degradation inducing tag and usage thereof | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-04-13 | — | — | US | disclosed |
| US-20210088504-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20200283761-A1 | METHOD FOR PRODUCING COMPLEX OF RNA MOLECULE AND PEPTIDE, AND UTILIZATION THEREOF | CUBICSTARS, INC. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20180164289-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20140296223-A1 | METHOD FOR REGULATING SKIN PIGMENTATION | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
| CN-103917229-A | Method of regulating skin pigmentation | GEN HOSPITAL CORP | 2014-07-09 | — | — | CN | disclosed |
| WO-2013033520-A1 | A METHOD FOR REGULATING SKIN PIGMENTATION | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10976306-B2 | Protein degradation inducing tag and usage thereof | SENP8, SENP6, SENP7 | NPEPPS 102/4885ANPEP 167/4885SMN1; SMN2 4697/4885 |
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TP53, TP53BP1, MDM2 | NPEPPS 774/4885ANPEP 649/4885SMN1; SMN2 4754/4885 |
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | KRAS, G3BP1, NRAS | NPEPPS 440/4885ANPEP 785/4885SMN1; SMN2 4496/4885 |
| US-20180164289-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | SENP8, SENP6, SENP7 | NPEPPS 102/4885ANPEP 167/4885SMN1; SMN2 4697/4885 |
| US-20210088504-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | SENP8, SENP6, SENP7 | NPEPPS 102/4885ANPEP 167/4885SMN1; SMN2 4697/4885 |
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | NPEPPS 2766/4885ANPEP 2831/4885SMN1; SMN2 3821/4885 |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TP53, TP53BP1, MDM2 | NPEPPS 774/4885ANPEP 649/4885SMN1; SMN2 4754/4885 |
| US-20210277044-A1 | NOVEL MOLECULES FOR TARGETING RIBOSOMES AND RIBOSOME-INTERACTING PROTEINS, AND USES THEREOF | RRBP1, RPLP1, MRPS18B | NPEPPS 637/4885ANPEP 1711/4885SMN1; SMN2 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.